EKF Diagnostics is a global manufacturer of diagnostic instruments and reagents, specializing in point-of-care equipment for measuring glucose, lactate, hemoglobin, hematocrit, and glycated hemoglobin (HbA1C). The company offers a range of products, including hemoglobin analyzers like DiaSpect and Hemo Control, glucose and lactate analyzers such as Biosen and Quo-Lab A1c, and various laboratory equipment like chemistry analyzers and centrifuges. EKF also provides contract manufacturing services and distributes third-party products. Its customer base includes hospitals, laboratories, and government agencies across regions including Europe, the Middle East, the Americas, Asia, and Africa. Founded in 1990 and headquartered in Cardiff, UK, EKF Diagnostics focuses on diverse medical fields including diabetes, hematology, infectious diseases, and clinical chemistry.
A GI-focused digital health company offering an evidence-based, clinically validated condition management program that integrates a resilience-based behavior change approach with live one-on-one coaching and user-friendly apps proven to improve overall resilience, enhance self-management, promote better mental health and lower costs of care for individuals living with inflammatory bowel disease (Crohn's Disease and Ulcerative Colitis) and Irritable Bowel Syndrome.
DiaSpect Medical AB
Acquisition in 2014
DiaSpect Medical AB develops hemoglobin measurement systems.
Selah Genomics is a clinical diagnostic specialist supporting healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. Selah's services add value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helps clinicians and healthcare providers treat and monitor patients, thereby improving patient outcomes.
Separation Technology Inc.
Acquisition in 2014
Separation Technology Inc. provides centrifugation solutions to the laboratory marketplace.
360 Genomics Ltd.
Acquisition in 2013
360 Genomics Ltd. develops molecular diagnostic technologies for the detection of mutations in key oncogenes.
Argutus Medical is a world leader in developing and manufacturing specialised organ injury assays. Argutus Medical primarily focuses on developing ELISA tests and lateral flow rapid test devices for detection of acute kidney injury (Nephrotoxicity) and acute liver injury (Hepatotoxicity). Argutus also manufactures a range of other assays including OxyDNA, a unique test for oxidative DNA damage (Genotoxicity). Argutus Medical was previously part of Biotrin International before branching out in 2008. In 2010 Argutus Medical was acquired by EKF Diagnostics Holdings plc, a rapidly growing global health care company. Being part of EKF Diagnostics has allowed Argutus Medical to continue to focus on biomarker discovery and development of novel biomarker assays from their facility in Dublin, Ireland.
Quotient Diagnostics Ltd.
Acquisition in 2010
Quotient Diagnostics Ltd. develops a testing technology for the diagnosis, treatment, and management of diabetes and associated diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.